History shows us that what tobacco companies say is often very different from what they actually do. They work hard to try to convince the public and governments that they’re changing for the better. But monitoring and analysis of their business practices shows Big Tobacco appears to be willing to sacrifice human health for profits—no matter what it says.
To kick off a new year in the fight against Big Tobacco, experts from the partners in STOP share predictions for what we’ll hear from tobacco companies in 2022, and what they’ll actually do.
What they’ll say: “We’re solving the smoking epidemic with our new electronic products.”
What they’ll likely do: Continue selling cigarettes while also targeting young people with new addictive products.
Instead of supporting tobacco control policies that help reduce smoking, Big Tobacco’s proposed solution to the smoking epidemic appears to be switching its customers to its new (and profitable) products. But e-cigarettes are also ending up in the hands of young people around the world, and it’s not a coincidence.
“The tobacco industry is using social media, event sponsorship and flavors to deliberately attract young people, particularly in low- and middle-income countries,” says Gan Quan, Director of Tobacco Control at The Union. Young people risk becoming addicted to these products, and even increase their likelihood of taking up cigarettes in the future. “There is an increasing body of evidence that youth who use e-cigarettes, who have never smoked, increase their chance of smoking traditional cigarettes later in life by two to four fold,” he adds. If Big Tobacco continues making cigarettes at its current rate, tobacco companies will produce and sell hundreds of billions of cigarettes in 2022 alone.
What they’ll say: “We’re in the business of health.”
What they’ll likely do: Continue acquiring health-focused companies while profiting from tobacco-related disease.
In 2021, we saw Philip Morris International (PMI), the largest transnational tobacco company in the world, acquire a medical inhaler company, Vectura, that makes products used to treat tobacco-related illnesses. “PMI is now able to profit twice from the tobacco epidemic: Once when a customer buys its cigarettes, and then again when they buy a Vectura inhaler to treat an illness which may be caused or worsened by smoking, such as asthma,” says Jorge Alday, Director at Vital Strategies. Unless these acquisitions are prevented, more tobacco companies may use their dirty money to buy their way into the healthcare space in 2022.
This is a major risk, as it allows tobacco companies to publicly advertise that they’re in the business of health, despite selling products that kill 8 million people every year. “It’s an attempt to buy credibility through so-called corporate social responsibility and distract attention from the colossal harm of their products,” says Tom Hird, Research Fellow at the Tobacco Control Research Group at the University of Bath. “When tobacco companies portray themselves as contributing to health, they could regain the trust of the public and get opportunities to work with governments, the way PMI has in securing a partnership with the Canadian government on the COVID vaccine it’s helping to fund.”